AMCP Nexus 2021 Updates on iGlarLixi in Type 2 Diabetes

March 01, 2022

An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.